CRVS Pump?
Float and volume are looking good along with the percentage gain so far. Read the news and watch this into earnings! Just taking a little note here to check back later in my new scanner parameters!
CRVS trade ideas
CRVS Short Entry and CoverI put an order our premarket to go short CRVS at the 3.50 level at 3.45. With a target half way back to the 3.00 level at 3.21. The reason I made my target half way to the 3.00 support is not entirely clear to me. Something about how the stock is not very extended, and how volume has been low. it felt a bit like it has been consolidating. And I didn't want to push my luck for it to turn and break above 3.50. My target was hit around 1:35pm.
CRVS Has a float of 41.55M, a low short float, a market cap of 154.68M, and a net income of -40.90M. The stock is up 146% in 36 days, over its April break out.
On may 12th the company released press stating "positive" results from a phase 1 study on there drug candidate CP-818, an oral ITK inhibitor, which is currently being evaluated as a single-agent therapy in a phase I/Ib
On May 9th Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating.
May 10th was the day of the break out above 1.50, a major price resistance.
CRVS Covered at lossI covered some CRVS today at a loss. I am currently too lazy to look and get all of the details.
KalaGhazi | Corvus Pharmaceuticals Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment
On Wednesday, the company said it will present new data for CPI-818 at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland from June 13 to 17.
$CRVSCorvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
$CRVS Corvus Pharmaceuticals Potential Friday Pump Pt's
Hopefully you find the chart helpful in terms of Supports & Resistance etc.
we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice.
Thank you for taking time to consult our chart and we would really appreciate a like, follow or comment.
$CRVS Bullish Bat CRVS has a Bullish Bat
HOP Levels: .24 cents
.382 fib $3.75
.618 fib $4.93
on the weekly chart it is a strong green candle, but as for the Daily candle we do have a major gap, meaning we could refill that GAP between $2.53 - $3.57
CRVS - Long Setup Downward channel breakout insider a larger downward channel. Break 2.86 Target 3.43 and Target 2 5.43. Would consider stop of 2.37. Larger risk as stock as already just broken out. January $5.00 calls had 262 contracts traded on Friday. Price is 0.19 cents. $2.50 calls are 0.70.
My CRVS Price TargetsHello all,
As you all may have noticed from doing your research that there has been a quantifiable spike in insider buying by the President and Director of Orbimed Advisors.
On February 17th, 2021 there was an Initial Public Offering at $3.50/share.
I have not made any extensive due diligence on the company yet, solely interested in the high amount of shares bought up by insiders.
Thank you
CRVS Long IdeaMultiple insider buying, huge institutional purchase at $3.50, and clear stop-loss below it. Low risk high reward play. First target is $5.
$CRVS is gonna to fall todayPupm&Dump trading strategy idea.
$CRVS is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $5,51;
stop-loss — $6,3.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
CRVS consolidationConsolidation in TF wk is that's all I could say.
Modulating immune system play role in cancer and infection.
In cancer treatment targeted therapy and tailed play major role (High cost of drug of course)
CRVS do the modulating immune system thing
Now let's see what's CRVS do.
What the physicians want is "When can we use this medication/protocol?"
It's phase 3 to use in human before FDA approves
Phase 3 is important when you do research
Here what's they do
COVID
Phase 1 CPI-006 (B cell activation -> immune system thing about white blood cell)
CANCER
Phase 1B-2 Ciforadenant Renal cell, prostate
Phase 1 CPI 818 T-cell lymphoma (white blood cell cancer)
etc.
So the factors that the price will surge are:-
-Positive Research outcome
-Phase 3
-FDA approve
that's all
EW count for CRVSLeading diagonal completed, now in wave 2.
Out of all stocks biotech is probably the most susceptible to wrong Elliott wave counts because they are volatile due to news and trial results having a heavy influence on the stock. Nevertheless, this is a view of what the future may hold.
Rip through ceilingGreen lines are the stopping volume. It is in Accumulation phase now. Shall go higher
